Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aspira Womens HealthAWHL -12.06%38 EV-to-EBITDA is -2.14 as of Aug. 13, 2026. GuruFocus rates AWHL with a GF Score™ of 38/100 and a GF Value™ of $0.28 (Modestly Overvalued). The stock has 8 warning signs investors should review. Among 118 Medical Diagnostics & Research companies, Aspira Womens Health ranks worse than 847456.78% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Aspira Womens Health's enterprise value is $19.30 Mil.
Aspira Womens Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-9.01 Mil. Therefore, Aspira Womens Health's EV-to-EBITDA for today is -2.14.
The historical rank and industry rank for Aspira Womens Health's EV-to-EBITDA or its related term are showing as below:
AWHL'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -53.07 Med: -2.87 Max: -0.03
Current: -2.14
During the past 13 years, the highest EV-to-EBITDA of Aspira Womens Health was -0.03. The lowest was -53.07. And the median was -2.87.
AWHL's EV-to-EBITDA is ranked worse than 100% of 118
companies
in the Medical Diagnostics & Research industry
Industry Median: 16.065
vs AWHL: -2.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Aspira Womens Health (OTCPK:AWHL) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Aspira Womens Health's PE Ratio (TTM) for today is calculated as:
Aspira Womens Health's share price for today is $0.35.
Aspira Womens Health's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.320.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Aspira Womens Health's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Aspira Womens Health's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aspira Womens Health EV-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Aspira Womens Health's EV-to-EBITDA falls into.
Aspira Womens Health's current Enterprise Value is $19.30 Mil.
Aspira Womens Health's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.01 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aspira Womens Health (AWHL) has a EV-to-EBITDA of -2.14 as of Aug. 13, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspira Womens Health. According to the industry distribution chart, Aspira Womens Health ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry.
Is Aspira Womens Health's EV-to-EBITDA too high?
Aspira Womens Health's current EV-to-EBITDA is -2.14. Based on the distribution chart, Aspira Womens Health ranks #999999 out of 118 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Aspira Womens Health has a GF Score™ of 38/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Aspira Womens Health's EV-to-EBITDA compare to MDXH and QUCY?
According to the Medical Diagnostics & Research industry distribution chart, Aspira Womens Health ranks #999999 out of 118 companies for EV-to-EBITDA. This places Aspira Womens Health in the lower half of its industry. The industry median EV-to-EBITDA is 16.07. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Diagnostics & Research company?
The median EV-to-EBITDA among Medical Diagnostics & Research companies is 16.07, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Aspira Womens Health. For the Medical Diagnostics & Research industry, the median EV-to-EBITDA is 16.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aspira Womens Health's current EV-to-EBITDA is -2.14. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aspira Womens Health stock overvalued right now?
Based on GuruFocus' analysis, Aspira Womens Health (AWHL) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.28, compared to a current price of $0.35 — trading 25% above its estimated fair value. The current EV-to-EBITDA is -2.14. Aspira Womens Health's overall GF Score™ is 38/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Aspira Womens Health (AWHL), the current EV-to-EBITDA is -2.14 as of Aug. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aspira Womens Health (AWHL) Overvalued in 2026?
Based on GuruFocus' analysis, Aspira Womens Health stock appears to be overvalued.
The current stock price of $0.35 is trading 25% above its estimated GF Value™ of $0.28.
GuruFocus considers Aspira Womens Health to be Modestly Overvalued.
Key valuation signals for AWHL:
EV-to-EBITDA: -2.14
GF Value™: $0.28 vs. price of $0.35 (25% above fair value)
No single metric tells the full story. See the AWHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. Its main products include OvaWatch, Ova1Plus, Ova1, and Overa, which are used to assess ovarian cancer risk in women with adnexal masses. The company is also developing EndoCheck for endometriosis. The company views its operations and manages its business in a single operating segment, which is the discovery, development, and commercialization of noninvasive diagnostic tests.
38GF Score
Get the complete analysis for AWHL
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AWHL has been successfully added to your 
